In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 211 to 220 of 375

TitleTypeExpected publication date
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Technology appraisal guidance
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]Technology appraisal guidanceTBC
Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]Technology appraisal guidanceTBC
Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Technology appraisal guidance
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Technology appraisal guidanceTBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]Technology appraisal guidanceTBC
Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]Technology appraisal guidance
Non-invasive skin closure devices for surgical incisions (MT775)Medical technologies guidanceTBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All